Showing results (61-70 of 203) with videos related to
Sort By:
Pageof 21
The Journal of Biological Chemistry|January 24, 2003
Persistent ERK phosphorylation negatively regulates cAMP response element-binding protein (CREB) activity via recruitment of CREB-binding protein to pp90RSKZiqiu Wang, Baochun Zhang, Meifang Wang, et al.Digestive Diseases and Sciences|November 30, 2007
Chemo-embolization for unresectable hepatocellular carcinoma with different sizes of embolization particlesNikhil B Amesur, Albert B Zajko, Brian I CarrDigestive Diseases and Sciences|January 27, 2007
Clinical evaluation of lens culinaris agglutinin-reactive alpha-fetoprotein and des-gamma-carboxy prothrombin in histologically proven hepatocellular carcinoma in the United StatesBrian I Carr, Futoshi Kanke, Margaret Wise, et al.Medical Hypotheses|July 4, 2016
A systemic evolutionary approach to cancer: Hepatocarcinogenesis as a paradigmAntonio Mazzocca, Giovanni Ferraro, Giovanni Misciagna, et al.Cell Biology International|May 11, 2007
Growth inhibitory actions of prothrombin on normal hepatocytes: influence of matrixBrian I Carr, Siddhartha Kar, Meifang Wang, et al.Journal of Gastrointestinal Cancer|October 6, 2021
Relationships Between Indices of Tumor Aggressiveness in Hepatocellular CarcinomaBrian I Carr, Vito Guerra, Rossella Donghia, et al.Hepatology (Baltimore, Md.)|November 30, 2007
Grb2-associated binder-1 plays a central role in the hepatocyte growth factor enhancement of hepatoma growth inhibition by K vitamin analog compound 5Ziqiu Wang, Lisheng Ge, Meifang Wang, et al.Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|July 27, 2005
Proxy ratings of health related quality of life in patients with hepatocellular carcinomaJennifer L Steel, David A Geller, Brian I CarrDigestive Diseases and Sciences|April 10, 2007
Posttraumatic growth, immunity and survival in patients with hepatomaJames T Dunigan, Brian I Carr, Jennifer L SteelJournal of Gastroenterology and Hepatology|November 3, 2010
Economic evaluation of sorafenib in unresectable hepatocellular carcinomaBrian I Carr, Stuart Carroll, Noemi Muszbek, et al.Pageof 21